Success Metrics

Clinical Success Rate
80.8%

Based on 21 completed trials

Completion Rate
81%(21/26)
Active Trials
8(17%)
Results Posted
43%(9 trials)
Terminated
5(11%)

Phase Distribution

Ph phase_4
6
13%
Ph early_phase_1
1
2%
Ph phase_1
6
13%
Ph not_applicable
5
11%
Ph phase_2
13
28%
Ph phase_3
15
32%

Phase Distribution

7

Early Stage

13

Mid Stage

21

Late Stage

Phase Distribution46 total trials
Early Phase 1First-in-human
1(2.2%)
Phase 1Safety & dosage
6(13.0%)
Phase 2Efficacy & side effects
13(28.3%)
Phase 3Large-scale testing
15(32.6%)
Phase 4Post-market surveillance
6(13.0%)
N/ANon-phased studies
5(10.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

67.7%

21 of 31 finished

Non-Completion Rate

32.3%

10 ended early

Currently Active

8

trials recruiting

Total Trials

47

all time

Status Distribution
Active(8)
Completed(21)
Terminated(10)
Other(8)

Detailed Status

Completed21
unknown8
Recruiting6
Terminated5
Withdrawn5
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
47
Active
8
Success Rate
80.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (2.2%)
Phase 16 (13.0%)
Phase 213 (28.3%)
Phase 315 (32.6%)
Phase 46 (13.0%)
N/A5 (10.9%)

Trials by Status

unknown817%
active_not_recruiting24%
completed2145%
terminated511%
withdrawn511%
recruiting613%

Recent Activity

Clinical Trials (47)

Showing 20 of 47 trialsScroll for more
NCT06290141Phase 3

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Recruiting
NCT04078568Phase 3

Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease

Completed
NCT06920004Phase 3

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

Recruiting
NCT06015750Phase 4

Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

Withdrawn
NCT03939637Phase 3

Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

Completed
NCT04935177Phase 3

Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx

Completed
NCT04400994Phase 2

IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus

Active Not Recruiting
NCT05614128

Validation of Cutaneous Nerve Demyelination in Diagnosis and Treatment of CIDP

Terminated
NCT04474223Phase 3

Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)

Recruiting
NCT03647852Not Applicable

Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura

Recruiting
NCT06064279Phase 1

Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC

Withdrawn
NCT03919773Phase 1

IVIG (Gamunex-C) Treatment Study for POTS Subjects

Completed
NCT06577909Phase 2

Prednisone Plus IVIg vs. Prednisone for ITP During Pregnancy

Recruiting
NCT06534450Phase 3

The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics

Active Not Recruiting
NCT06423989Not Applicable

Role of Immunoglobulin in Male Infertility

Recruiting
NCT06089122Phase 3

Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG

Unknown
NCT05799716Phase 4

Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections

Unknown
NCT01769027Phase 2

Antibiotic Treatment and Intravenous Immunoglobulin Trial for PANDAS

Withdrawn
NCT03065244Phase 3

KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)

Completed
NCT02659891Phase 1

IVIg to Treat BK Viremia in Kidney Transplant Recipients

Completed

Drug Details

Intervention Type
DRUG
Total Trials
47